Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
| Id | http://purl.obolibrary.org/obo/dinto_DB00082
http://purl.obolibrary.org/obo/dinto_DB00082
|
|---|---|
| Preferred Name | pegvisomant |
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | pegvisomant
|
|---|---|
| label | pegvisomant
|
| DBSynonym |
somatotropin precursor
pituitary growth hormone
growth hormone
growth hormone 1
gh-n
gh
See more
See less
|
| ATCCode | H01AX01
|
| Definition | Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
|
| has pharmacological target | |
| induces | |
| inhibits | |
| type | |
| blocks | |
| AHFScode | 68:30.08
|
| xref |
PharmGKB:PA164749630
UniProtKB:P58756
GenBank:AF374232
RxList:http://www.rxlist.com/cgi/generic3/somavert.htm
National Drug Code Directory:0009-5176-01
Drugs Product Database (DPD):2272199
Drugs.com:http://www.drugs.com/cdi/pegvisomant.html
See more
See less
|
| CASRN | 218620-50-9
|
| prefixIRI | obo2:dinto_DB00082
|
| may interact with | |
| DBBrand | somavert (pfizer inc)
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |